Introduction
============

The azatriquinane derivatives are an important substance class in organic chemistry containing nitrogen and three fused five-membered rings \[[@R1]--[@R3]\]. Due to the unique rigid bowl-shaped structure with one noninversible electron lone pair at the bottom of the central nitrogen ("*centro*-N") atom, 10-azatriquinane analogues are used as efficient chelation reagents of metal cations \[[@R4]--[@R5]\]. Mascal and colleagues \[[@R6]\] described the first synthesis of 10-azatriquinane (**1**) from dimethyl 3,3\'-(1*H*-pyrrole-2,5-diyl)dipropanoic acid in five steps, and the reactivity of **1** was also investigated. 10-azatriquinane (**1**) is very active because of its high basicity. The X-ray structure of **1**·HBF~4~ revealed that the *centro*-N is pyramidalized. 10-azatriquinacene (**2**), an unsaturated analogue of **1**, was attractive due to its high proton affinity \[[@R7]\]. Recently, Mascal \[[@R8]\] and colleagues have developed a series of 10-azatriquinanes as a *C* ~3~ *~v~*-symmetric platform for tripodal metal complexes and calixiform scaffolds ([Fig. 1](#F1){ref-type="fig"}).

![The structures of azatriquinanes and azatriquinacene.](Beilstein_J_Org_Chem-09-265-g002){#F1}

Previously, we established a facile access to enantiopure asymmetric *cis*-2,5-disustituted pyrrolidines **4** from commercially available starting materials diethyl *meso*-2,5-dibromoadipate and (*S*)-(−)-1-phenylethylamine ([Fig. 2](#F2){ref-type="fig"}) \[[@R9]\]. The preparations of compounds **5a**, **5b**, **6a** and **6b** were also reported in \[[@R9]\], but our previously published structures for compounds **5a** and **5b** were not completely correct, because the B--N dative bonds were missing. The aim of the following procedures was to obtain several novel bifunctional *N*-hetereocyclic carbenes (NHCs) \[[@R10]--[@R14]\] from compounds **4** through three steps, including reduction, debenzylation and cyclization ([Scheme 1](#C1){ref-type="fig"}), but this failed. However, we have found a novel one-pot tandem cyclization of these enantiopure asymmetric *cis*-2,5-disubstituted pyrrolidines to produce chiral trisubstituted 10-heteroazatriquinane derivatives. To the best of our knowledge, there is very little research on the synthesis of 10-heteroazatriquinanes, and the chiral 10-heteroazatriquinanes are unknown up to now.

![The synthesis of **4** (*previous work*).](Beilstein_J_Org_Chem-09-265-g003){#F2}

![The designed synthetic route to a hydroxy NHC from **4b**.](Beilstein_J_Org_Chem-09-265-g007){#C1}

Results and Discussion
======================

For the reduction of highly hindered amides **4**, the system of LiAlH~4~ in anhydrous THF was found to be useless even upon heating under reflux for 18 h under an inert atmosphere, and no desired diamino-alcohols were obtained after workup. However, **4a** reacted smoothly with BH~3~ to give white crystals after chromatographic purification ([Scheme 2](#C2){ref-type="fig"}). The X-ray single-crystal diffraction analysis established that the reduction product **5a** ([Fig. 3](#F3){ref-type="fig"}) was formed with a rigid 10-heteroazaquinane skeleton through an intramolecular Lewis acid--base pair interaction \[[@R15]--[@R18]\]. Three five-membered rings are fused to give a very stable bowl-shaped tricyclic system with five stereogenic centers, especially for one chiral nitrogen center and one chiral boron center. The configurations of the stereogenic centers in **5a** are deduced from the configuration of the chiral auxiliary (*S*)-(−)-1-phenylethylamine to be *S*, 3*S*, 6*R*, 9*S* (chiral B atom) and 10*R* (chiral N atom), respectively. This novel tandem reduction/cyclization was made possible by the *cis*-configuration of the starting 2,5-disubstituted pyrrolidine **4a**. Following the same procedure, 10-heteroazaquinane **5b** was obtained in good yield (87%), and the configurations of **5b** were assigned to be *S*, 3*R*, 6*S*, 9*R* (chiral B atom) and 10*S* (chiral N atom), respectively. Compounds **5a** and **5b** are diastereomers.

![The reduction of amides **4** by LiAlH~4~ and BH~3~·THF.](Beilstein_J_Org_Chem-09-265-g008){#C2}

![X-ray crystal structure of compound **5a**.](Beilstein_J_Org_Chem-09-265-g004){#F3}

In the presence of a catalytic amount of Pd(OH)~2~/C, under 1.0 atm of hydrogen, the above 10-heteroazaquinane derivatives **5** were converted into enantiopure asymmetric *cis*-2,5-disubstituted pyrrolidines **6** in good yields with a diamino-alcohol skeleton. In this process, both *N*-debenzylation and a ring-opening reaction occurred. Diamino-alcohols **6a** and **6b** are enantiomers, and they can serve as precursors for the synthesis of hydroxy *N*-heterocyclic carbenes. Following the reported procedure for the preparation of *N*-heterocyclic carbenes \[[@R19]--[@R20]\], the enantiopure pyrrolidine **6b** and NH~4~BF~4~ in HC(OCH~3~)~3~ is heated to 80 °C for 2 h, the light yellow crystals were obtained in good yield after workup ([Scheme 3](#C3){ref-type="fig"}). The same result was obtained by heating the mixture of **6b**, NH~4~BF~4~ and HC(OCH~3~)~3~ in anhydrous toluene under reflux.

![One-pot tandem cyclization of **6** in the presence of HC(OCH~3~)~3~.](Beilstein_J_Org_Chem-09-265-g009){#C3}

To our delight, a single crystal was grown from CH~2~Cl~2~, suitable for X-ray diffraction analysis. It was found that the ring-closing reaction took place during the heating process following *N*-methylation to provide the rigid 1-oxo-3-aza-10-azaquinane skeleton **7b** as its ammonium salt. Compound **7b** contains four stereogenic centers, and their configurations are assigned to be 2*R*, 5*S*, 8*R* and 10*R* (chiral N atom) based on its starting material **4b** ([Fig. 4](#F4){ref-type="fig"}). Actually, HC(OCH~3~)~3~ as an efficient reagent for *C*-, *N*-, and *O*-methylation has been reported \[[@R21]--[@R24]\], but the mechanism of these methylations is elusive. The other chiral ammonium salt **7a** was obtained under the same conditions as those for the preparation of **7b**. The chiral ammonium salts **7a** and **7b** were derived from the enantiomers **6a** and **6b**, therefore, **7a** and **7b** are also enantiomers. The configurations of **7a** are assigned to be 2*S*, 5*R*, 8*S* and 10*S* (chiral N atom).

![X-ray crystal structure of compound **7b**.](Beilstein_J_Org_Chem-09-265-g005){#F4}

As shown in [Fig. 4](#F4){ref-type="fig"}, this 10-heteroazatriquinane **7b** possesses a rigid bowl-like molecular scaffold with a quaternary nitrogen site (N2) at the bottom of the cavity. Recently, Denmark and colleagues \[[@R25]--[@R26]\] have synthesized a series of chiral phase-transfer catalysts (chiral PTCs) based on a 2-azatriquinane skeleton ([Fig. 5](#F5){ref-type="fig"}), and they have investigated their catalytic activities in asymmetric alkylation reactions for producing enantiomerically enriched amino acids. The synthesis of these quaternary ammonium ions follows a diversity-oriented approach wherein the tandem inter-\[4 + 2\]/intra-\[3 + 2\] cycloaddition of nitroalkenes serves as the key transformation. The chiral ammonium salts **7** have a structure similar to the chiral PTCs of Denmark et al. The substituents in the chiral ammonium salts **7** are easily tunable, which could open a route to various chiral PTCs for organic synthesis.

![The structural comparison of chiral ammonium salts such as **7** with the chiral PTCs of Denmark et al.](Beilstein_J_Org_Chem-09-265-g006){#F5}

Conclusion
==========

In summary, we provide here a facile access to chiral 10-heteroazatriquinanes from enantiopure asymmetric *cis*-2,5-disubstituted pyrrolidines through one-pot tandem cyclization reactions, and their configurations are confirmed by X-ray single-crystal diffraction analysis. The applications of these novel 10-heteroazatriquinanes are currently being investigated in our laboratory.
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